During the past 12 months, Matinas BioPharma Holdings's average Total Assets Growth Rate was -14.20% per year.
During the past 3 years, the average Total Assets Growth Rate was -2.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 8.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 34.20% per year.
During the past 11 years, Matinas BioPharma Holdings's highest 3-Year average Total Assets Growth Rate was 126.10%. The lowest was -2.60%. And the median was 18.00%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Matinas BioPharma Holdings Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Matinas BioPharma Holdings (AMEX:MTNB) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Matinas BioPharma Holdings's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Matinas BioPharma Holdings Total Assets Related Terms
Thank you for viewing the detailed overview of Matinas BioPharma Holdings's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Matinas BioPharma Holdings (Matinas BioPharma Holdings) Business Description
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MTNB has been successfully added to your 